PAION AG

PAION AG: Sale of the business operations

PAION AG: Sale of the business operations

PAION AG cancelled guidance for financial year 2023

PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD

PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL

PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS – PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED

PAION AG: Filing an application for the opening of insolvency proceedings

PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights

PAION AG to issue approximately 4.8 million shares in capital increase with subscription rights

PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million

PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million

PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN

PAION receives UK MHRA approval of Byfavo® (remimazolam) for the induction and maintenance of general anesthesia in adults

PAION AG reports financial results for the First Half-Year 2023

PAION launches Byfavo® (remimazolam) in the first European country for General Anesthesia

Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG

PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES

 PAION AG SUCCESSFULLY HOLDS ITS ANNUAL GENERAL MEETING 2023

PAION AG: Bekanntmachung der Einberufung zur Hauptversammlung am 12.07.2023 in Aachen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

​​​​​​​PAION IS HOSTING A SPONSORED BYFAVO® SYMPOSIUM AT  EUROANAESTHESIA 2023 IN GLASGOW

PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023

POSTPONEMENT OF PUBLICATION OF THE ANNUAL AND CONSOLIDATED FINANCIAL STATEMENTS 2022

PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults

PAION AG implements resolved capital reduction

Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

PAION AG reports on fiscal year 2022

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS